title: Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease.
abstract: Pulmonary arterial hypertension (PAH) occurs in approximately 15% of patients with systemic sclerosis (SSc). Annual screening with pulmonary function tests (PFT) is recommended to help identify those patients at risk of PAH. We have noted that patients with SSc who carry anti-centromere autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical evidence of PAH. To evaluate this further, we undertook a retrospective case-control study evaluating PFT results in patients with SSc in whom pulmonary complications have neither been diagnosed nor suspected. Patients were divided according to ACA carriage and groups compared for PFT results. The median forced vital capacity (FVC) was higher in ACA-positive patients (106 vs. 93%, p=0.004). The gas transfer factor (TLco) was significantly lower in the ACA group (62.5 vs. 71%, p=0.013). The resulting FVC:TLco was significantly higher for ACA-positive vs. ACA-negative patients with SSc (1.70 vs. 1.29, p<0.001). Our findings suggest patients carrying ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. The long-term sequelae of PFT abnormalities in those patients with ACA who do not subsequently develop PAH are unknown.
authors.affiliation: Royal National Hospital for Rheumatic Disease, Bath, UK.
authors.forename: J
authors.initials: J
authors.lastname: Gunn
authors.forename: J D
authors.initials: JD
authors.lastname: Pauling
authors.forename: N J
authors.initials: NJ
authors.lastname: McHugh
mesh_terms: D000368:Aged; D000906:Antibodies / Q000276:immunology*; D016022:Case-Control Studies; D002503:Centromere / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000150:complications / Q000276:immunology; D008171:Lung Diseases / Q000097:blood* / Q000150:complications / Q000276:immunology*; D008875:Middle Aged; D015203:Reproducibility of Results; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000097:blood* / Q000150:complications / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000906:Antibodies
references.citation: Arthritis Rheum. 2003 Feb;48(2):516-22
references.pmid: 12571862
references.citation: Ann Rheum Dis. 2003 Nov;62(11):1088-93
references.pmid: 14583573
references.citation: J Rheumatol. 1988 Feb;15(2):202-5
references.pmid: 3361530
references.citation: Arthritis Rheum. 1988 Feb;31(2):196-203
references.pmid: 3348823
references.citation: J Rheumatol. 2008 Mar;35(3):458-65
references.pmid: 18203320
references.citation: Heart. 2008 Mar;94 Suppl 1:i1-41
references.pmid: 18276826
references.citation: Circulation. 2009 Apr 28;119(16):2250-94
references.pmid: 19332472